molecules of the month


IV/SC glutamine antimetabolite prodrug

Ph. I/IIa in advanced solid tumors

dual prodrug of natural product

Sci. Adv., 16 November 2022

Johns Hopkins / Dracen Pharmaceuticals

sirpiglenastat chemical structure IV/SC glutamine antimetabolite prodrug- Johns Hopkins / Dracen Pharmaceuticals
3 mins read

A first-in-class diazo-prodrug for the treatment of solid tumors. Sirpiglenastat (DRP-104) (Johns Hopkins/Dracen Pharmaceuticals) is a dual prodrug of 6-diazo-5-oxo-l-norleucine (DON), a diazoketone-based glutamine irreversible antagonist used to suppress cancer cell metabolism. Rapidly growing cancer cells depend on glutamine as an energy source via the tricarboxylic acid (TCA) cycle, as well as a carbon and nitrogen source for biosynthesis and cellular homeostasis. Thus, approaches to blocking glutamine uptake or metabolism, such as glutaminase inhibitors like telaglenastat (Calithera, Ph. I/II) have been investigated. Although DON itself demonstrated promising preclinical and clinical efficacy, the program was terminated due to dose-limiting gastrointestinal (GI) toxicities. As a dual prodrug that is selectively activated in tumor cells and deactivated in GI tissues, sirpiglenastat has a…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: